Search

Displaying 1 - 14 of 14

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

Condition: Cancer / Leukemia

Status: Currently Recruiting

This study is for 1 to 21-year-olds whose hematologic cancer has relapsed to take medication called Tagraxofusp. Relapse means that cancer has come back after treatment. Tagraxofusp is a drug approved by the FDA (Food and Drug Administration) but is not approved to treat the cancers of people in this study. This study is being done to find out if…

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

Condition: Cancer / Leukemia

Investigator: Nobuko Hijiya, MD

Status: Currently Recruiting

This study will enroll with children, adolescents and young adults that are less than 22 years old that have returned or 'relapsed' acute myeloid leukemia (AML) diagnoses. Within this group, the study is also targeting those are also unable to receive additional chemotherapy treatments containing anthracycline, which is a type of antibiotic that…

A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML

Condition: Cancer / Leukemia

Investigator: Nobuko Hijiya, MD

Status: Currently Recruiting

This is a phase 1 study for participants with relapsed/refractory acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or juvenile myelomonocytic leukemia (JMML) diagnosis. This study will observe the safety, side effects, and best dose of Imetelstat as an investigational drug, or drug that is not approved by the Food and Drug Administration (FDA…

Study of BLU-263 in Patients with Indolent Systemic Mastocytosis (ISM) or Monoclonal Mast Cell Activation Syndrome (mMCAS)

Condition: Cancer / Leukemia

Investigator: Joseph Jurcic, MD

Status: Currently Recruiting

You are being asked to participate in this study because you have indolent SM (ISM) or because you have Monoclonal mast cell activation syndrome (mMCAS). Currently, there are no available targeted therapies for patients with ISM or mMCAS. The study will test the drug BLU-263. BLU-263 is a new study drug that is being developed for treating people like you,…

Study of Polatuzumab Vedotin in Combination with Chemotherapy in Subjectswith Richter's Transformation

Condition: Cancer / Leukemia

Investigator: Andrew Lipsky, MD

Status: Currently Recruiting

This research is being done because Richter's transformation, which is a life-threatening complication of chronic lymphocytic lymphoma (CLL), and is associated with poor overall survival rate. The study drug administration is a combination of the investigational drug, Polatuzumab vedotin, in combination with Rituximab, Etoposide, Prednisone,…

Study of SEA-CD70 in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Condition: Cancer / Leukemia

Investigator: Joseph Jurcic, MD

Status: Currently Recruiting

You are being asked to participate in this study because you have Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) and we are testing the study drugs, SEA-CD70, to find out what its side effects are and to see if the study drug is safe for people with these types of cancer are testing to see if SEA-CD70 is safe for people, and its side effects…

Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias (Children and Young Adults)

Condition: Cancer / Leukemia

Investigator: Nobuko Hijiya, MD

Status: Currently Recruiting

This study is called a screening study and the purpose of this study to find better ways to diagnose and treat leukemia that has come back after treatment or difficult to treat. Bone marrow, blood, and medical information about cancer and treatment will be collected. The results from this screening study may give other information about leukemia that is…